Health Catalyst Q2 Earnings Call Highlights
Health Catalyst NASDAQ: HCAT reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook, while outlining a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Health Catalyst (HCAT) Beats Q2 Earnings and Revenue Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.04 per share a year ago.
Health Catalyst Investors Approve Directors, Pay; Board Declassification Fails
Health Catalyst NASDAQ: HCAT stockholders approved three of four proposals presented at the company's 2026 annual meeting, including the election of two directors, ratification of the company's auditor and an advisory vote on executive compensation. A proposal to phase out the company's classified board structure did not receive the required level of support.
Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript
Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript
Health Catalyst Q1 Earnings Call Highlights
Health Catalyst NASDAQ: HCAT reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company's operating model, reducing costs and shifting the business further toward technology-led growth.
Health Catalyst (HCAT) Q1 Earnings and Revenues Surpass Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.01 per share a year ago.
Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Health Catalyst (HCAT) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Hold” by Brokerages
Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average recommendation of "Hold" from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The
Health Catalyst (HCAT) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.04 per share a year ago.
